Literature DB >> 26143282

Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study.

Vasileios Andrianopoulos1, Emiel F M Wouters2, Victor M Pinto-Plata3, Lowie E G W Vanfleteren4, Per S Bakke5, Frits M E Franssen4, Alvar Agusti6, William MacNee7, Stephen I Rennard8, Ruth Tal-Singer9, Ioannis Vogiatzis10, Jørgen Vestbo11, Bartolome R Celli12, Martijn A Spruit13.   

Abstract

In addition to the six-min walk distance (6 MWD), other six-min walk test (6 MWT) derived variables, such as mean walk-speed (6MWSpeed), 6-min walk-work (6 MWW), distance-saturation product (DSP), exercise-induced oxygen desaturation (EID), and unintended stops may be useful for the prediction of mortality and hospitalization in patients with chronic obstructive pulmonary disease (COPD). We studied the association between 6 MWT-derived variables and mortality as well as hospitalization in COPD patients and compared it with the BODE index. A three-year prospective study (ECLIPSE) to evaluate the prognostic value of 6 MWT-derived variables in 2010 COPD patients. Cox's proportional-hazard regressions were performed to estimate 3-year mortality and hospitalization. During the follow-up, 193 subjects died and 622 were hospitalized. An adjusted Cox's regression model of hazard ratio [HR] for impaired 6 MWT-derived variables was significant referring to: mortality (6 MWD ≤334 m [2.30], 6MWSpeed ≤0.9 m/sec [2.15], 6 MWW ≤20000 m kg [2.17], DSP ≤290 m% [2.70], EID ≤88% [1.75], unintended stops [1.99]; and hospitalization (6 MWW ≤27000 m kg [1.23], EID ≤88% [1.25], BODE index ≥3 points [1.40]; all p ≤ 0.05). The 6 MWT-derived variables have an additional predictive value of mortality in patients with COPD. The 6 MWW, EID and the BODE index refine the prognosis of hospitalization.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPD; Exercise physiology; Exercise testing; Hospitalization; Mortality; Prognostic markers

Mesh:

Year:  2015        PMID: 26143282     DOI: 10.1016/j.rmed.2015.06.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  29 in total

1.  Body composition and sarcopenia in patients with chronic obstructive pulmonary disease.

Authors:  Tatiana Munhoz da Rocha Lemos Costa; Fabio Marcelo Costa; Thaísa Hoffman Jonasson; Carolina Aguiar Moreira; César Luiz Boguszewski; Victória Zeghbi Cochenski Borba
Journal:  Endocrine       Date:  2018-02-05       Impact factor: 3.633

2.  Measurement properties of the Timed Up & Go test in patients with COPD.

Authors:  Rafael Mesquita; Sarah Wilke; Dionne E Smid; Daisy Ja Janssen; Frits Me Franssen; Vanessa S Probst; Emiel Fm Wouters; Jean Wm Muris; Fabio Pitta; Martijn A Spruit
Journal:  Chron Respir Dis       Date:  2016-07-08       Impact factor: 2.444

Review 3.  Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement.

Authors:  Priya Agarwala; Steve H Salzman
Journal:  Chest       Date:  2019-11-02       Impact factor: 9.410

4.  Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD.

Authors:  Vladimir Fijačko; Marina Labor; Mirjana Fijačko; Sanda Škrinjarić-Cincar; Slavica Labor; Iva Dumbović Dubravčić; Tatjana Bačun; Aleksandar Včev; Sanja Popović-Grle; Davor Plavec
Journal:  Wien Klin Wochenschr       Date:  2018-01-10       Impact factor: 1.704

5.  Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study.

Authors:  J Michael Wells; Raul San Jose Estepar; Merry-Lynn N McDonald; Surya P Bhatt; Alejandro A Diaz; William C Bailey; Francine L Jacobson; Mark T Dransfield; George R Washko; Barry J Make; Richard Casaburi; Edwin J R van Beek; Eric A Hoffman; Frank C Sciurba; James D Crapo; Edwin K Silverman; Craig P Hersh
Journal:  BMC Pulm Med       Date:  2016-12-01       Impact factor: 3.317

6.  Usefulness of the 6-minute walk test as a screening test for pulmonary arterial enlargement in COPD.

Authors:  Yutaro Oki; Masahiro Kaneko; Yukari Fujimoto; Hideki Sakai; Shogo Misu; Yuji Mitani; Takumi Yamaguchi; Hisafumi Yasuda; Akira Ishikawa
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-22

7.  Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Masakazu Ichinose; Yoshiaki Minakata; Takashi Motegi; Jun Ueki; Tetsuo Seki; Tatsuhiko Anzai; Ayako Takizawa; Lars Grönke; Kazuto Hirata
Journal:  Adv Ther       Date:  2017-05-23       Impact factor: 3.845

Review 8.  Frailty, a Dimension of Impaired Functional Status in Advanced COPD: Utility and Clinical Applicability.

Authors:  Sabina Antonela Antoniu; Lucian Vasile Boiculese; Virgiliu Prunoiu
Journal:  Medicina (Kaunas)       Date:  2021-05-11       Impact factor: 2.430

9.  Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.

Authors:  Masakazu Ichinose; Yoshiaki Minakata; Takashi Motegi; Jun Ueki; Yasuhiro Gon; Tetsuo Seki; Tatsuhiko Anzai; Shuhei Nakamura; Kazuto Hirata
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-01

10.  Validation of exhaled volatile organic compounds analysis using electronic nose as index of COPD severity.

Authors:  Panaiotis Finamore; Claudio Pedone; Simone Scarlata; Alessandra Di Paolo; Simone Grasso; Marco Santonico; Giorgio Pennazza; Raffaele Antonelli Incalzi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.